Description

Overview
Semaglutide (NNC0113-0217) is a synthetic, long-acting Glucagon-like Peptide-1 (GLP-1) receptor agonist peptide that has become one of the most scientifically significant and widely studied metabolic research compounds of the modern era. Structurally derived from native human GLP-1 with 94% sequence homology, Semaglutide incorporates key molecular modifications — including a C18 fatty diacid chain attached via a linker to lysine at position 26 — that confer exceptional albumin binding, protease resistance, and an extended pharmacokinetic half-life. Apex Sequence Labs offers Semaglutide at the highest purity standards, rigorously tested and manufactured under strict quality control protocols to ensure consistency and reliability for advanced scientific investigation.

Molecular Profile

Full Name: Semaglutide (NNC0113-0217)
Type: Long-Acting GLP-1 Receptor Agonist
Molecular Formula: C???H???N??O??
Molecular Weight: ~4113.6 g/mol
CAS Number: 910463-68-2
Purity: ?99% (HPLC verified)
Form: Lyophilized powder
Half-Life: Approximately 7 days (designed for once-weekly dosing in research models)
GLP-1 Sequence Homology: 94% to native human GLP-1

Research Areas of Interest
As one of the most clinically advanced and extensively peer-reviewed peptide molecules in modern biomedical science, Semaglutide has generated a vast and growing body of research across numerous disciplines:

Glucose Metabolism & Glycaemic Control – The cornerstone of Semaglutide research, its potent GLP-1 receptor agonism drives glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and slows gastric emptying, resulting in significantly improved postprandial and fasting glucose profiles. Extensively studied in type 2 diabetes models, Semaglutide has consistently demonstrated superior HbA1c reductions across a broad range of preclinical and clinical research settings.
Obesity & Body Weight Research – One of the most transformative areas of Semaglutide investigation, landmark clinical trials have documented unprecedented reductions in body weight through its central and peripheral effects on appetite regulation and energy homeostasis. Research has explored its differential effects on fat mass versus lean mass, subcutaneous versus visceral adipose tissue, and the durability of weight reduction across extended study periods.
Cardiovascular Research – Among the most significant findings in contemporary cardiometabolic science, Semaglutide has been extensively studied for its cardioprotective properties. Research has documented meaningful reductions in major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular mortality in high-risk populations, establishing it as a landmark compound in cardiovascular outcome research.
Neurological & Cognitive Research – An emerging and rapidly expanding frontier, Semaglutide has attracted significant scientific interest for its potential neuroprotective and neuroregenerative properties. Research has explored its effects on neuroinflammation, dopaminergic signalling, amyloid plaque accumulation, tau pathology, and cognitive function, positioning it as a subject of active investigation in Alzheimer’s disease, Parkinson’s disease, and broader neurodegenerative disease research.
Hepatic Research & Liver Disease – Investigated for its potent effects on hepatic fat accumulation, liver inflammation, and fibrosis markers, Semaglutide has emerged as one of the most promising investigational compounds in NAFLD and NASH research. Studies have documented significant reductions in liver fat content, ALT normalisation, and histological improvement in preclinical and early clinical research models.
Renal & Nephroprotective Research – Studied for its nephroprotective properties in models of diabetic and non-diabetic kidney disease, with research documenting reductions in albuminuria, preservation of glomerular filtration rate (GFR), and attenuation of renal inflammatory markers, contributing to a growing body of evidence on GLP-1 receptor agonism in kidney disease research.
Addiction & Reward Pathway Research – A particularly novel and rapidly growing area of scientific interest, preclinical and emerging clinical research has begun exploring Semaglutide’s effects on dopaminergic reward circuitry and its potential to modulate addictive behaviours, including alcohol consumption, nicotine dependence, and substance use disorders, opening entirely new research frontiers beyond metabolic science.
Inflammation & Immunological Research – Investigated for its broad anti-inflammatory properties, including modulation of pro-inflammatory cytokines, reduction of C-reactive protein (CRP), and attenuation of systemic inflammatory markers in metabolic and non-metabolic disease models, suggesting potential research applications beyond classical endocrinological contexts.
Polycystic Ovary Syndrome (PCOS) Research – Studied in models of PCOS-associated metabolic and hormonal dysregulation, with research examining its effects on insulin resistance, androgen excess, menstrual regularity, and reproductive outcomes, contributing to growing scientific interest in GLP-1 receptor agonism in reproductive endocrinology.
Musculoskeletal Research – Emerging research has begun to explore Semaglutide’s effects on bone metabolism, muscle mass preservation, and musculoskeletal health in the context of significant weight reduction, addressing important questions about the composition of weight loss and its long-term implications for skeletal integrity.

What Sets Semaglutide Apart?
Semaglutide’s scientific significance stems from a combination of structural innovation and unparalleled clinical validation:

Albumin Binding via Fatty Acid Chain – The C18 fatty diacid modification enables non-covalent albumin binding in circulation, dramatically extending half-life and enabling once-weekly research dosing protocols
Protease Resistance – Substitution of alanine with ?-aminoisobutyric acid (Aib) at position 8 confers resistance to DPP-4 degradation, a key structural advancement over native GLP-1
CNS Penetration – Research has demonstrated Semaglutide’s ability to cross the blood-brain barrier and engage central GLP-1 receptors in hypothalamic and reward-related brain regions, underpinning its emerging neurological research applications
Breadth of Clinical Evidence – With data from landmark trials including SUSTAIN, STEP, PIONEER, FLOW, and SELECT programmes, Semaglutide has one of the most extensive clinical evidence bases of any research peptide compound, providing researchers with an exceptionally well-characterised reference compound
Multi-System Research Utility – Its demonstrated effects across metabolic, cardiovascular, neurological, hepatic, renal, and immunological systems make Semaglutide uniquely versatile as a multi-disciplinary research tool

Quality Assurance
All Apex Sequence Labs peptides are:

Synthesized using advanced solid-phase peptide synthesis (SPPS)
Third-party tested via HPLC and Mass Spectrometry
Produced in a controlled, sterile, ISO-compliant laboratory environment
Fatty acid chain conjugation verified through analytical testing
Supplied with a Certificate of Analysis (CoA) available upon request

Packaging & Storage

Available in: 2mg | 5mg | 10mg vials
Storage: Store lyophilized peptide at 20°C away from light and moisture
Once reconstituted: Store at 4°C and use within 28 days
Recommended diluent: Bacteriostatic water or sterile water for injection
Shelf life: 24 months when stored correctly in lyophilized form

Why Choose Apex Sequence Labs?

– 99% purity guaranteed
– Independent third-party testing on every batch
– Certificate of Analysis provided
– Produced in ISO-compliant cleanroom facilities
– Fast, discreet shipping
– Dedicated researcher support team

– Research Use Only Disclaimer
Semaglutide supplied by Apex Sequence Labs is intended strictly for in vitro and in vivo laboratory research purposes only. This product is NOT intended for human or veterinary use, is NOT a drug or dietary supplement. While Semaglutide (brand names Ozempic®, Wegovy®, Rybelsus®) is an FDA-approved pharmaceutical product manufactured by Novo Nordisk, the research-grade Semaglutide supplied by Apex Sequence Labs is an independently synthesised research compound and is not affiliated with, endorsed by, or equivalent to any approved pharmaceutical product. By purchasing this product, the buyer confirms they are a qualified researcher and accepts full responsibility for its lawful and ethical use in accordance with all applicable local, state, and federal regulations.